Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Short Interest Update

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 4,200 shares, a drop of 45.5% from the November 30th total of 7,700 shares. Based on an average daily volume of 17,600 shares, the days-to-cover ratio is currently 0.2 days.

Scinai Immunotherapeutics Trading Up 2.7 %

SCNI opened at $3.44 on Friday. The firm has a market capitalization of $2.93 million, a price-to-earnings ratio of -0.01 and a beta of 2.43. Scinai Immunotherapeutics has a one year low of $2.23 and a one year high of $8.92. The business has a 50 day simple moving average of $3.37 and a two-hundred day simple moving average of $3.61. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.16 and a quick ratio of 1.16.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.